Response to letter to the editor in response to “Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer”

✍ Scribed by David M. O'Malley

• Book ID: 113963465
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 123 KB
• Volume: 124
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2011.09.030